Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05159765 · ClinicalTrials.gov registry record · NA
Progressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial
A NA study of Myopia, sponsored by Visioneering Technologies.
- Active
- Registry status
- NA
- Development phase
- 144
- Enrollment target
- 8
- Study locations
NCT05159765: Active NA study of Myopia, sponsored by Visioneering Technologies.
NCT05159765 is a NA study of Myopia that is active but no longer recruiting, run by Visioneering Technologies. The registered enrollment target is 144 participants, below the 266-participant average among 90 other Myopia trials with a reported enrollment target (46% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05159765, a NA study of Myopia, is active but no longer recruiting, sponsored by Visioneering Technologies.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 144 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a multi-center, randomized, double-masked clinical trial. All study devices are market approved/cleared in the localities where the study is conducted. Subjects will be randomly assigned to wear NaturalVue Sphere single vision contact lenses (SVCL) or NaturalVue Multifocal (NVMF) soft contact lenses for a total of three years.
Primary Outcome
Mean change in cycloplegic auto-refraction (D)
Conditions Studied
Interventions
- DEVICE Multifocal contact lenses
- DEVICE Single vision contact lenses
Study Locations (8)
Ontario
- Toronto Eye Care - Toronto
- University of Waterloo School of Optometry - Waterloo
Other
- Hong Kong Polytechnic University - Tsim Sha Tsui
- Myopia Specialist Centre - Singapore
California
- Fig Garden Optometry - Fresno
Illinois
- North Suburban Vision Consultants - Deerfield
New York
- Cooper Eye Care - New York
Texas
- Bellaire Family Eye Care - Bellaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2022-01-22 |
| Est. Completion | 2026-02 |
| Phase | NA |
What the registry record for NCT05159765 still lists
NCT05159765 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 266-participant average among 90 other Myopia trials with a reported enrollment target (46% lower).
The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which Multifocal contact lenses is the first listed.
NCT05159765 lists 8 locations in 6 states (Ontario, Other, California).
Frequently Asked Questions
What is clinical trial NCT05159765 about?
NCT05159765 is a clinical study titled "Progressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial". This is a multi-center, randomized, double-masked clinical trial. All study devices are market approved/cleared in the localities where the study is conducted. Subjects will be randomly assigned to wear NaturalVue Sphere single vision contact lenses (SVCL) or NaturalVue Multifocal (NVMF) soft contac...
What is the current status of trial NCT05159765?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 144 participants. The study started on 2022-01-22. Estimated completion is 2026-02.
What conditions does trial NCT05159765 study?
This clinical trial studies the following conditions: Myopia.
What interventions are being tested in trial NCT05159765?
The interventions under investigation include: Multifocal contact lenses (DEVICE), Single vision contact lenses (DEVICE).
Who is sponsoring clinical trial NCT05159765?
This trial is sponsored by Visioneering Technologies, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05159765 being conducted?
This trial has 8 study locations across California, Illinois, New York, Texas, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05159765's enrollment target sits among peer trials
144 31st of 90 higher than 60 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
-
Wavelength Intervention for Nearsighted Kids
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI